2nd Circ. Skeptical Of Bid To Boost Drug Royalty Award
A Second Circuit panel appeared unsympathetic during oral arguments on Wednesday to Acorda Therapeutics Inc.'s assertion that it should be awarded nearly $66 million beyond the $16.5 million it won in...To view the full article, register now.
Already a subscriber? Click here to view full article